Related Experiment Video

Updated: Mar 7, 2026

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
14:59

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus

Published on: October 14, 2022

11.2K

Rate and Risk Factors for Shunt Revision in Pediatric Patients with Hydrocephalus-A Population-Based Study

Joona Tervonen1, Ville Leinonen1, Juha E Jääskeläinen1

  • 1Department of Neurosurgery, NeuroCenter, Kuopio University Hospital, Kuopio, Finland.

World Neurosurgery
|February 19, 2017
PubMed

Insights

Half of pediatric hydrocephalus patients needed shunt revision, with younger infants and those with congenital defects or intraventricular hemorrhage facing higher risks. Most revisions occurred within the first year post-Ventriculoperitoneal Shunt placement.

Area of Science:

  • Pediatric Neurosurgery
  • Hydrocephalus Management
  • Shunt Technology

Background:

  • Ventriculoperitoneal shunt (VPS) is a primary treatment for pediatric hydrocephalus (HC).
  • Complications associated with VPS often necessitate shunt revisions.
  • Understanding surgical outcomes in a population-based setting is crucial for improving patient care.

Purpose of the Study:

  • To investigate the surgical outcomes of pediatric patients undergoing Ventriculoperitoneal Shunt (VPS) placement for hydrocephalus (HC).
  • To identify risk factors associated with shunt revision in pediatric HC patients.
  • To analyze the impact of hydrocephalus etiology and patient age on shunt survival rates.

Main Methods:

  • Retrospective review of medical charts and imaging for 80 pediatric patients (≤16 years) with HC requiring VPS.
  • Analysis of shunt revision rates based on age at initial placement, etiology of HC, and type of valve used.
  • Comparison of shunt survival and revision rates across different patient subgroups.

Main Results:

  • 50% of patients required shunt revision, with a mean time to first revision of 8 months.
  • Infants ≤6 months old exhibited a significantly higher shunt revision rate compared to older children (P < 0.001).
  • Hydrocephalus secondary to intraventricular hemorrhage (67% revision rate) and congenital defects (72% revision rate) showed higher revision rates than tumors (32% revision rate).

Conclusions:

  • Approximately half of pediatric hydrocephalus patients treated with VPS require revision surgery.
  • Younger age (≤6 months) and specific etiologies (intraventricular hemorrhage, congenital defects) are significant risk factors for shunt revision.
  • The majority of shunt revisions occur within the first year following the initial VPS placement.
Abstract

Keywords:
HydrocephalusPediatricPopulation-basedRevisionsShunting

More Related Videos

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:20

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

652
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.7K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
625
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
450
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
471